Polymorphisms in cytochrome P450 2C19 enzyme and cessation of leflunomide in patients with rheumatoid arthritis.

Arthritis Res Ther · 2012 · PMC3580556 · PMID 22784880

Europe PMC DOI

hedged sentence

0.1800

closest p · 3.6× alpha

0.1800

boldest claim

The sentences

did not reach statistical significanceP = 0.18not close (p > 0.1)

Other variables that were associated with cessation rate were current use of a 20 mg daily dose (Hazard Ratio = 1.68, 95% CI 0.79 to 3.56) and use of triple DMARD therapy at the time of leflunomide initiation (Hazard Ratio = 2.2, 95% CI 0.97 to 5.2), but these did not reach statistical significance ( P = 0.18 and 0.057 respectively).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.